Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Mar 29, 2025
Filed with the SEC on May 2, 2025 and accepted by EDGAR at May 2, 2025, 10:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-29 | $10.36bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2025-01-01 to 2025-03-29 | $342.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-01-01 to 2025-03-29 | $2.08bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-01-01 to 2025-03-29 | $1.72bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-29 | $303.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-29 | $95.0m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2025-01-01 to 2025-03-29 | $3.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-29 | $3.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-29 | 379,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-29 | $723.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-29 | $362.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2025-01-01 to 2025-03-29 | $149.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2025-01-01 to 2025-03-29 | $2.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-03-29 | $4.13bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-29 | $23.38bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-29 | $99.04bn | us-gaap:Assets |
| Current liabilities | At period end2025-03-29 | $13.17bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2025-03-29 | $33.99bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2025-03-29 | $2.82bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2025-03-29 | $49.39bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-03-29 | 377,493,912 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-25-000041. Last ingested by Listed: Nov 6, 2026, 03:40 ET. Listed shows no prices and gives no investment advice.